美国 · SEC FORM 4
Vir Biotechnology, Inc.
VIR · Nasdaq · CIK 0001706431 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
12 同一窗口内观察到的 Form 4 交易行
3 sales · 9 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
Showing the six most active owners; 4 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-03-01 · Sigal Charles Elliott.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 14,980,532
- 上期报告
- 19,660,671
- 日均成交量
- 2,138,348
- 回补天数
- 7.0
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-03-01 | Sigal Charles Elliott | 买入 (P) | Common Stock | 2,500 | USD 22.73 | USD 56,825 | SEC 申报 ↗ |
| 2023-01-05 | Sigal Charles Elliott | 买入 (P) | Common Stock | 2,500 | USD 24.96 | USD 62,400 | SEC 申报 ↗ |
| 2023-01-04 | Sigal Charles Elliott | 买入 (P) | Common Stock | 2,500 | USD 25.25 | USD 63,125 | SEC 申报 ↗ |
| 2023-01-03 | Sigal Charles Elliott | 买入 (P) | Common Stock | 2,500 | USD 25.60 | USD 64,000 | SEC 申报 ↗ |
| 2021-11-29 | HANLY ANN M. | 买入 (P) | Common Stock | 12 | USD 43.39 | USD 500 | SEC 申报 ↗ |
Form 4 申报证据
59 transaction lines in the latest 365-day window; 861 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | MORE ROBERT J | J (J) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Coughlin Timothy | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | Sabatini Brent | 卖出 (S) | Common Stock | 379 | USD 9.45 | USD 3,582 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | MORE ROBERT J | J (J) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-09 | Coughlin Timothy | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-01 | Sabatini Brent | 卖出 (S) | Common Stock | 379 | USD 9.45 | USD 3,582 | SEC 申报 ↗ |
| 2026-06-01 | Napolitano Janet | 卖出 (S) | Common Stock | 3,200 | USD 9.45 | USD 30,240 | SEC 申报 ↗ |
| 2026-05-27 | Sigal Charles Elliott | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Napolitano Janet | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | MORE ROBERT J | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Hatfield Jeffrey S. | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | Farid Ramy | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-27 | BISCHOFBERGER NORBERT W | 奖励／授予 (A) | Common Stock | 8,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-01 | SATO VICKI L | 卖出 (S) | Common Stock | 22,000 | USD 10.05 | USD 221,100 | SEC 申报 ↗ |
| 2026-04-29 | De Backer Marianne | J (J) | Common Stock | 233,532 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-04-06 | De Backer Marianne | 卖出 (S) | Common Stock | 72,559 | USD 9.16 | USD 664,640 | SEC 申报 ↗ |
| 2026-04-01 | SATO VICKI L | 卖出 (S) | Common Stock | 22,000 | USD 9.07 | USD 199,540 | SEC 申报 ↗ |
| 2026-03-23 | Sabatini Brent | 卖出 (S) | Common Stock | 7,711 | USD 9.12 | USD 70,324 | SEC 申报 ↗ |
| 2026-03-20 | O'Byrne Jason | J (J) | Common Stock | 2,500 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-02 | SATO VICKI L | 卖出 (S) | Common Stock | 22,000 | USD 9.50 | USD 209,096 | SEC 申报 ↗ |
| 2026-02-25 | de Verneuil Vanina | 卖出 (S) | Common Stock | 13,700 | USD 9.82 | USD 134,534 | SEC 申报 ↗ |
| 2026-02-25 | Eisner Mark | 卖出 (S) | Common Stock | 1,889 | USD 9.82 | USD 18,550 | SEC 申报 ↗ |
| 2026-02-24 | de Verneuil Vanina | 卖出 (S) | Common Stock | 3,117 | USD 9.53 | USD 29,705 | SEC 申报 ↗ |
| 2026-02-24 | Sabatini Brent | 卖出 (S) | Common Stock | 1,430 | USD 9.53 | USD 13,628 | SEC 申报 ↗ |
| 2026-02-24 | SATO VICKI L | 卖出 (S) | Common Stock | 42,377 | USD 9.75 | USD 413,278 | SEC 申报 ↗ |
| 2026-02-24 | SATO VICKI L | 期权行权／转换 (M) | Common Stock | 42,377 | USD 1.49 | USD 63,142 | SEC 申报 ↗ |
| 2026-02-24 | O'Byrne Jason | 卖出 (S) | Common Stock | 1,634 | USD 9.53 | USD 15,572 | SEC 申报 ↗ |
| 2026-02-24 | Eisner Mark | 卖出 (S) | Common Stock | 1,616 | USD 9.53 | USD 15,400 | SEC 申报 ↗ |
| 2026-02-24 | De Backer Marianne | 卖出 (S) | Common Stock | 14,762 | USD 9.53 | USD 140,682 | SEC 申报 ↗ |
| 2026-02-23 | de Verneuil Vanina | 卖出 (S) | Common Stock | 4,445 | USD 7.45 | USD 33,115 | SEC 申报 ↗ |
| 2026-02-23 | Sabatini Brent | 卖出 (S) | Common Stock | 1,829 | USD 7.45 | USD 13,626 | SEC 申报 ↗ |
| 2026-02-23 | O'Byrne Jason | 卖出 (S) | Common Stock | 2,089 | USD 7.45 | USD 15,563 | SEC 申报 ↗ |
| 2026-02-23 | Eisner Mark | 卖出 (S) | Common Stock | 2,089 | USD 7.45 | USD 15,563 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | VIR |
| CIK | 0001706431 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 861 transaction lines from 2020-04-03 to 2026-08-11 5 P purchase lines · 428 S sale lines · 428 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.